A
Andres M. Salazar
Researcher at University of California, Los Angeles
Publications - 83
Citations - 7752
Andres M. Salazar is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Immune system & Antigen. The author has an hindex of 32, co-authored 83 publications receiving 6123 citations. Previous affiliations of Andres M. Salazar include University of California, Irvine & Icahn School of Medicine at Mount Sinai.
Papers
More filters
Journal ArticleDOI
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott,Zhuting Hu,Derin B. Keskin,Derin B. Keskin,Sachet A. Shukla,Sachet A. Shukla,Jing Sun,David J. Bozym,Wandi Zhang,Adrienne M. Luoma,Anita Giobbie-Hurder,Lauren Peter,Christina Chen,Oriol Olive,Todd A. Carter,Shuqiang Li,David J. Lieb,Thomas Eisenhaure,Evisa Gjini,Jonathan Stevens,William J. Lane,Indu Javeri,Kaliappanadar Nellaiappan,Andres M. Salazar,Heather Daley,Michael S. Seaman,Elizabeth I. Buchbinder,Elizabeth I. Buchbinder,Charles H. Yoon,Maegan Harden,Niall J. Lennon,Stacey Gabriel,Scott J. Rodig,Scott J. Rodig,Dan H. Barouch,Dan H. Barouch,Dan H. Barouch,Jon C. Aster,Jon C. Aster,Gad Getz,Gad Getz,Kai W. Wucherpfennig,Donna Neuberg,Jerome Ritz,Jerome Ritz,Eric S. Lander,Eric S. Lander,Edward F. Fritsch,Edward F. Fritsch,Nir Hacohen,Nir Hacohen,Catherine J. Wu +51 more
TL;DR: The feasibility, safety, and immunogenicity of a vaccine that targets up to 20 predicted personal tumour neoantigens is demonstrated and a strong rationale for further development of this approach, alone and in combination with checkpoint blockade or other immunotherapies is provided.
Journal ArticleDOI
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Derin B. Keskin,Annabelle J. Anandappa,Jing Sun,Itay Tirosh,Nathan Mathewson,Shuqiang Li,Giacomo Oliveira,Anita Giobbie-Hurder,Kristen Felt,Evisa Gjini,Sachet A. Shukla,Zhuting Hu,Letitia Li,Phuong M. Le,Rosa Lundbye Allesøe,Rosa Lundbye Allesøe,Alyssa R. Richman,Monika S. Kowalczyk,Sara Abdelrahman,Jack Geduldig,Sarah Charbonneau,Kristine Pelton,J. Bryan Iorgulescu,Liudmila Elagina,Wandi Zhang,Oriol Olive,Christine McCluskey,Lars Rønn Olsen,Jonathan Stevens,William J. Lane,Andres M. Salazar,Heather Daley,Patrick Y. Wen,E. Antonio Chiocca,Maegan Harden,Niall J. Lennon,Stacey Gabriel,Gad Getz,Eric S. Lander,Aviv Regev,Jerome Ritz,Donna Neuberg,Scott J. Rodig,Keith L. Ligon,Mario L. Suvà,Kai W. Wucherpfennig,Nir Hacohen,Edward F. Fritsch,Kenneth J. Livak,Patrick A. Ott,Catherine J. Wu,David A. Reardon +51 more
TL;DR: It is demonstrated that a strategy that uses multi-epitope, personalized neoantigen vaccination, which has previously been tested in patients with high-risk melanoma, is feasible for tumours such as glioblastoma, which typically have a relatively low mutation load and an immunologically ‘cold’ tumour microenvironment.
Journal ArticleDOI
Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant.
M. Paula Longhi,Christine Trumpfheller,Juliana Idoyaga,Marina Caskey,Ines Matos,Courtney Kluger,Andres M. Salazar,Marco Colonna,Ralph M. Steinman +8 more
TL;DR: The adjuvant action of poly IC requires a widespread innate type I IFN response that directly links antigen presentation by DCs to adaptive immunity, which is required in both marrow–derived and radioresistant host cells for adaptive responses.
Journal ArticleDOI
Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.
Hideho Okada,Pawel Kalinski,Ryo Ueda,Aki Hoji,Gary Kohanbash,Teresa E. Donegan,Arlan Mintz,Johnathan A. Engh,David L. Bartlett,Charles K. Brown,Herbert J. Zeh,Matthew P. Holtzman,Todd A. Reinhart,Theresa L. Whiteside,Lisa H. Butterfield,Ronald L. Hamilton,Douglas M. Potter,Ian F. Pollack,Andres M. Salazar,Frank S. Lieberman +19 more
TL;DR: These data support safety, immunogenicity, and preliminary clinical activity of poly-ICLC-boosted αDC1-based vaccines.
Journal ArticleDOI
Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans
Marina Caskey,Francois Lefebvre,Abdelali Filali-Mouhim,Mark J. Cameron,Jean-Philippe Goulet,Elias K. Haddad,Gaëlle Breton,Christine Trumpfheller,Sarah Pollak,Irina Shimeliovich,Angela Duque-Alarcon,Li Pan,Annette Nelkenbaum,Andres M. Salazar,Sarah J. Schlesinger,Ralph M. Steinman,Rafick Pierre Sekaly +16 more
TL;DR: As shown by transcriptional analysis of blood samples from human volunteers, injection with synthetic dsRNA triggered up-regulation of genes involved in innate immune pathways, similar to those induced by vaccination with the efficacious yellow fever vaccine.